Importer of Controlled Substances; Notice of Application; Clinical Supplies Management, Inc., 54913 [2013-21735]
Download as PDF
<![CDATA[
54913
Federal Register / Vol. 78, No. 173 / Friday, September 6, 2013 / Notices
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
Authority: These investigations are being
terminated under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 201.10 of the
Commission’s rules (19 CFR 201.10).
By order of the Commission.
Issued: September 3, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–21725 Filed 9–5–13; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Clinical Supplies
Management, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on July 22, 2013, Clinical Supplies
Management, Inc., 342 42nd Street
South, Fargo, North Dakota 58103, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites, conducting FDAapproved clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with D listed in schedule II,
which falls under the authority of
section 1002(a)(2)(B) of the Act 21
U.S.C. 952 (a)(2)(B) may, in the
circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 7, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 29, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–21735 Filed 9–5–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; United States
Pharmacopeial Convention
By Notice dated May 22, 2013, and
published in the Federal Register on
May 30, 2013, 78 FR 32457, United
States Pharmacopeial Convention,
12601 Twinbrook Parkway, Rockville,
Maryland 20852, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
Cathinone (1235) .........................................................................................................................................................................................
Methaqualone (2565) ..................................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
Marihuana (7360) ........................................................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ..............................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
Codeine-N-oxide (9053) ..............................................................................................................................................................................
Difenoxin (9168) ..........................................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Morphine-N-oxide (9307) .............................................................................................................................................................................
Norlevorphanol (9634) .................................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Phenmetrazine (1631) .................................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Amobarbital (2125) ......................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Glutethimide (2550) .....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (8333) ...................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Alphaprodine (9010) ....................................................................................................................................................................................
Anileridine (9020) ........................................................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Diphenoxylate (9170) ..................................................................................................................................................................................
VerDate Mar<15>2010
18:05 Sep 05, 2013
Jkt 229001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
E:\FR\FM\06SEN1.SGM
06SEN1
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 78, Number 173 (Friday, September 6, 2013)]
[Notices]
[Page 54913]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-21735]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application;
Clinical Supplies Management, Inc.
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on July 22, 2013, Clinical Supplies Management, Inc.,
342 42nd Street South, Fargo, North Dakota 58103, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of Sufentanil (9740), a basic class of controlled
substance listed in schedule II.
The company plans to import the listed controlled substance with
the sole purpose of packaging, labeling, and distributing to customers
which are qualified clinical sites, conducting FDA-approved clinical
trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with D listed in schedule II, which falls under the
authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B)
may, in the circumstances set forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the proposed registration and may, at
the same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 7, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: August 29, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-21735 Filed 9-5-13; 8:45 am]
BILLING CODE 4410-09-P
